Abstracts tagged "prognostic factors and systemic sclerosis"

Abstract Number: 794 • 2018 ACR/ARHP Annual Meeting
Identification of an Immunodominant Epitope on Rnpc-3 As a Target of Autoantibodies in Patients with Systemic Sclerosis
Michael Mahler¹, Chelsea Bentow¹, Jay Milo¹, Marie Hudson^2,3, Murray Baron³, May Choi⁴ and Marvin J. Fritzler⁴, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²Division of Rheumatology, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada, ³Department of Medicine, McGill University, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…
Abstract Number: 1720 • 2018 ACR/ARHP Annual Meeting
Higher Neutrophil Count Predicts More Severe Skin/Lung Disease and Increased Mortality in Early Systemic Sclerosis
Rana Taherian¹, Vishnu Mohan¹, Jun Ying², Samuel Theodore¹, Julio Charles¹, Hau Pham¹, Minghua Wu³, Maureen D. Mayes³ and Shervin Assassi³, ¹University of Texas Health Science Center at Houston, Houston, TX, ²Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Our recent global blood transcript studies show that systemic sclerosis (SSc) patients have a prominent neutrophil signature. Mechanistic studies with neutrophils are hampered by…
Abstract Number: 787 • 2018 ACR/ARHP Annual Meeting
Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?
Maaike Boonstra¹, Maarten K. Ninaber², Nina Ajmone Marsan³, Hans U. Scherer¹, Tom W.J. Huizinga¹ and Jeska de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Heart and Lung Center; Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ³Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: SSc is known for its heterogeneous disease course in which anti-topoisomerase I antibodies (ATA) are associated with dcSSc and interstitial lung disease and therefore…
Abstract Number: 788 • 2018 ACR/ARHP Annual Meeting
Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients with Systemic Sclerosis
Susanne Van Wijngaarden¹, Maaike Boonstra², Bas Bloem³, Daniela Cassani⁴, Felix Tanner⁴, Suzana Jordan⁵, Oliver Distler⁶, Martin Jan Schalij³, V. Delgado¹, J.J. Bax¹, Jeska de Vries-Bouwstra⁷ and Nina Ajmone Marsan¹, ¹Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴University Heart Center, University Hospital Zurich, Zurich, Switzerland, ⁵Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Cardiac events are an important cause of mortality in Systemic Sclerosis (SSc), but its diagnosis remains challenging. Left ventricular global longitudinal strain is a…
Abstract Number: 793 • 2018 ACR/ARHP Annual Meeting
Clinical Associations of Anti-U11/U12 (RNPC-3) Autoantibodies in Patients with Systemic Sclerosis
Lorenzo Beretta¹, Michael Mahler², Chelsea Bentow², Andrea Seaman², Fabrece Roup², Michelle Amio², Karl Norvell², Jay Milo², Susan Encabo², Janire Perurena³, Maite Sanz³, Alfredo Guillen⁴, Ana Marín³, Vicent Fonollosa³, Eduardo Callejas³ and Carmen Pilar Simeón⁴, ¹Scleroderma Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Scleroderma Unit, Internal Medicine Department, Vall d’Hebron Hospital, Barcelona, Spain, ⁴Scleroderma Unit, Internal Medicine Department, Vall d’Hebron Hospital, Barcelona, Spain
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…
Abstract Number: 1486 • 2012 ACR/ARHP Annual Meeting
Poor Outcome in Patients with Systemic Sclerosis and Myocardial Involvement: A Combined Approach Based On Clinical and Laboratory Findings, EKG-Holter and Cardiac Magnetic Resonance
Silvia Laura Bosello, Giacomo De Luca, Antonella Laria, Giorgia Berardi and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Cardiac involvement is a relevant prognostic determinant in Systemic Sclerosis (SSc), but the diagnosis is often delayed due to the lack of a specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].